SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today Warren Jackman, M.D., joined the Company's Scientific Advisory Board.
"We are extremely excited to welcome Dr. Jackman to our Scientific Advisory Board," said Dr. Ed Brennan, Chief Executive Officer of CryoCor. "Dr. Jackman is a key thought leader in the field of cardiac arrhythmias and one of the most prominent electrophysiologists in the country for the treatment of atrial fibrillation. He has expressed an interest in evaluating our Cryoablation System for the treatment of AF, either as a stand-alone procedure, or in a combination procedure also using RF energy, to capitalize on the potential strengths of both energy sources. We are pleased to have another strong addition to our Scientific Advisory Board."
"My colleague, Dr. Hiroshi Nakagawa, and I have conducted several animal studies with CryoCor's Cryoablation System and are intrigued by the power, lesion size and potential safety from CryoCor's cryoablation system," said Dr. Warren Jackman. "I look forward to advising CryoCor as it evaluates its opportunity in the field of atrial fibrillation ablation."
Dr. Jackman has held active roles nationally in the Heart Rhythm Society (formerly the North American Society of Pacing and Electrophysiology) and served as director of a course on Advanced Catheter Ablation of Cardiac Arrhythmias at the American College of Cardiology. Dr. Jackman has also been an Investigator and Co-Investigator in grants from the American Heart Association, National Institutes of Health: National Heart Lung and Blood Institute, Oklahoma Health Research Program and the Whitaker Foundation.
Dr. Jackman obtained his medical degree from the University of Florida and completed his residency in Internal medicine at Bowman Gray School of Medicine, Wake Forest University. He served a Fellowship in cardiology and cardiac electrophysiology at Indiana University School of Medicine.
CryoCor's Scientific Advisory Board consists of leading physicians and researchers in the field of cardiology and cardiac electrophysiology and is active in assisting the Company's development of its products and clinical trials.
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the potential
advantages of CryoCor's cryoablation system and CryoCor's opportunities in
the field of atrial fibrillation ablation, all of which are prospective.
Such statements are only predictions and reflect CryoCor's expectations and
assumptions as of the date of this press release based on currently
available operating, financial, and competitive information. The actual
events or results may differ materially from those projected in such
forward-looking statements due to a number of factors, including risks
involved with CryoCor's technology and the diagnosis and treatment of
atrial arrhythmias; risks associated with the Company's dependence on
patents and proprietary rights; risks associated with the Company's
protection and enforcement of its patents and proprietary rights; risks
associated with the development or availability of competitive products or
technologies; risks associated with the Company's ability to maintain and
achieve milestones under collaborative agreements and the other risks and
uncertainties identified in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. The Company expressly disclaims any intent or obligation to
update any of these forward-looking statements.
Gregory J. Tibbitts
Chief Financial Officer
The Ruth Group
Nick Laudico / Zack Kubow (investors)
(646) 536-7030 / 7020
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved